Released March 25, 2011 | SUGAR LAND
en
Reported by Annette Kreuger, Industrial Info Resources (Sugar Land, Texas)--Industrial Info Resources is pleased to announce the release of the 2011 Pharmaceutical & Biotech Industry Outlook. With the entire industry--if not the world--in a state of transition, the importance of having a tool that provides understanding and knowledge has never been more essential. Tap into the pulse of the North American Pharmaceutical & Biotech Industry, using a clear, concise format that demystifies this lucrative and constantly evolving industry.
The 2011 Pharmaceutical & Biotech Industry Outlook for capital expenditures is estimated to be $18 billion, up from the actual $9 billion in 2010 project starts. Each year, Industrial Info Resources provides an overall spending forecast, with the numbers representing total expenditures for capital and maintenance as they relate to the North American Pharmaceutical & Biotech Industry. The forecast is derived by applying a confidence factor based on historical spending trends to the baseline project activity that Industrial Info is currently tracking. We then use actual projects identified from our research to analyze the trends, as they relate to geography, project type and budget type. As of March 24, 2011, the actual reported count for projects scheduled to begin construction during 2011 in North America was 757, representing a total investment value of $18 billion. These projects are measured on the scheduled kick-off date and are valued at $1 million and greater.
When using the 2011 Pharmaceutical & Biotech Industry Outlook, there is no need for the endless searching that often nets too much information that overwhelms rather than informs. Industrial Info has done the homework for you and packaged useful, timely and essential information and statistics into one easy-to-use format. Features include upcoming trends, vital plant and project statistics, as well as a capital and maintenance spending analysis derived from our information databases.
Setting the outlook apart from any aspiring competitors is that, in addition to having access to its clearly written editorial content, subscribers receive exclusive quarterly updates on 2011 plant and project spending statistics through our online version. It is important to understand that unlike other outlooks or forecasts that offer statistical information, our data is based on phone-verified project and plant information, conducted by our in-house staff of research specialists.
Be sure to check out the popular Annual Pharmaceutical/Biotech Industry Performance Lists. Filled with the latest data regarding the top companies' financials, best-selling products and more, this year's compilation is the largest yet. Lists included in the 2011 Pharmaceutical & Biotech Industry Outlook are as follows:
Company/Sector Data
If you will be in New York March 29-31 for the Interphex Pharmaceutical Convention, make sure to stop by Booth 1766 at the Jacob K. Javits Convention Center. We would be delighted to meet with you and give you a hands-on sample of our entire product line.
Gain instant access to the outlook today by subscribing online at Industrialinfo.com or contact our Member Center at 1-800-762-3361.
Industrial Info Resources (IIR) is the leading provider of global market intelligence specializing in the industrial process, heavy manufacturing and energy markets. IIR's quality-assurance philosophy, the Living Forward Reporting Principle, provides up-to-the-minute intelligence on what's happening now, while constantly keeping track of future opportunities.
The 2011 Pharmaceutical & Biotech Industry Outlook for capital expenditures is estimated to be $18 billion, up from the actual $9 billion in 2010 project starts. Each year, Industrial Info Resources provides an overall spending forecast, with the numbers representing total expenditures for capital and maintenance as they relate to the North American Pharmaceutical & Biotech Industry. The forecast is derived by applying a confidence factor based on historical spending trends to the baseline project activity that Industrial Info is currently tracking. We then use actual projects identified from our research to analyze the trends, as they relate to geography, project type and budget type. As of March 24, 2011, the actual reported count for projects scheduled to begin construction during 2011 in North America was 757, representing a total investment value of $18 billion. These projects are measured on the scheduled kick-off date and are valued at $1 million and greater.
When using the 2011 Pharmaceutical & Biotech Industry Outlook, there is no need for the endless searching that often nets too much information that overwhelms rather than informs. Industrial Info has done the homework for you and packaged useful, timely and essential information and statistics into one easy-to-use format. Features include upcoming trends, vital plant and project statistics, as well as a capital and maintenance spending analysis derived from our information databases.
Setting the outlook apart from any aspiring competitors is that, in addition to having access to its clearly written editorial content, subscribers receive exclusive quarterly updates on 2011 plant and project spending statistics through our online version. It is important to understand that unlike other outlooks or forecasts that offer statistical information, our data is based on phone-verified project and plant information, conducted by our in-house staff of research specialists.
Be sure to check out the popular Annual Pharmaceutical/Biotech Industry Performance Lists. Filled with the latest data regarding the top companies' financials, best-selling products and more, this year's compilation is the largest yet. Lists included in the 2011 Pharmaceutical & Biotech Industry Outlook are as follows:
Company/Sector Data
- Top 20 Pharmaceutical Company Rankings by 2009 Sales Revenue
- Top 10 Biotech Company Rankings by 2009 Sale Revenue
- Top 5 Generic Manufacturers by 2009 Sales Revenue
- Top 15 Pharmaceutical Stock 2010 Performance
- Top 10 Biopharmaceutical Stock 2010 Performance
- Major 2010 Layoff Announcements
- National Health Expenditures 2009
- PhRMA Member Companies
- Drug Industry Employment statistics for the United States
- Top 10 R&D Spending by Company 2009
- Top 10 Therapeutic Classes by Sales 2005-2009
- Top 20 Pharmaceutical Drugs by Sales 2009
- Top 10 Biotech Drugs by Sales 2009
- Top 10 Generic Drugs by Prescription Count 2009
- Top Drugs Losing Patent Protection 2011-2012
- Top Selling Vaccines 2007 - 2009
- Top 10 Industry Mergers
If you will be in New York March 29-31 for the Interphex Pharmaceutical Convention, make sure to stop by Booth 1766 at the Jacob K. Javits Convention Center. We would be delighted to meet with you and give you a hands-on sample of our entire product line.
Gain instant access to the outlook today by subscribing online at Industrialinfo.com or contact our Member Center at 1-800-762-3361.
Industrial Info Resources (IIR) is the leading provider of global market intelligence specializing in the industrial process, heavy manufacturing and energy markets. IIR's quality-assurance philosophy, the Living Forward Reporting Principle, provides up-to-the-minute intelligence on what's happening now, while constantly keeping track of future opportunities.
